To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
Trial · NCT01302899
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 (Day 1 to End of Week 6) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 4 | |
| Period 1 (Day 1 to End of Week 6) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 4 | |
| Period 1 (Day 1 to End of Week 6) | COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 4 | |
| Period 1 (Day 1 to End of Week 6) | COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 4 | |
| Period 1 (Day 1 to End of Week 6) | NOT COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 0 | |
| Period 1 (Day 1 to End of Week 6) | NOT COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 0 | |
| Period 2 (Weeks 7 to 12) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 4 | |
| Period 2 (Weeks 7 to 12) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 4 | |
| Period 2 (Weeks 7 to 12) | COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 3 | |
| Period 2 (Weeks 7 to 12) | COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 3 | |
| Period 2 (Weeks 7 to 12) | NOT COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 1 | |
| Period 2 (Weeks 7 to 12) | NOT COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 1 | |
| Period 3 (Weeks 13 to 18) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 3 | |
| Period 3 (Weeks 13 to 18) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 3 | |
| Period 3 (Weeks 13 to 18) | COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 3 | |
| Period 3 (Weeks 13 to 18) | COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 3 | |
| Period 3 (Weeks 13 to 18) | NOT COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 0 | |
| Period 3 (Weeks 13 to 18) | NOT COMPLETED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 0 | |
| Period 4 (Weeks 19 to 26) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram | 3 | |
| Period 4 (Weeks 19 to 26) | STARTED | Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01302899/flow